Most people think modern health fails because of bad science, bad actors, or lack of innovation.

That’s rarely the real problem.

Modern health breaks in the space between intent and execution, between what a clinic wants to do and what the system can actually support.

That gap is where outcomes drift, costs rise, and trust quietly erodes.

This newsletter exists to talk about that gap.

The same therapy, prescribed by two different clinics, can produce wildly different outcomes.

Not because the molecule changed.
Not because the patient changed.
But because the infrastructure around that decision did.

Modern health is no longer defined by what’s possible clinically.
It’s defined by what’s sustainable operationally.

Telehealth made access easier.
Compounding made customization possible.
Longevity made prevention attractive.

But none of those solved delivery.

They just exposed how fragile the system already was.

The obesity drug market is becoming a consumer category. Not in messaging. In actual distribution.

Pills launch in January. Cash pricing starts at $149 per month. No insurance needed. No prior authorization. Order online, ships direct. That's not how prescription medications typically work.

It's how consumer products work.

The numbers explain why this is happening. Three in four American adults are overweight or obese. Right now, one in eight is on a GLP-1. That gap represents the largest addressable market in pharmaceutical history.

Novo and Lilly aren't waiting for insurance to close it.

Injectables kept these drugs in medical channels. You needed someone to teach injection technique. You needed cold storage. You needed regular clinical touchpoints to manage titration. That infrastructure limited velocity.

Pills remove those requirements.

When you remove the requirements, you remove the gatekeepers. This is already visible in the data. Roughly 30% of Zepbound prescriptions move through cash-pay channels. That number climbs with oral formulations because the friction that justified medical oversight largely disappears.

Telehealth platforms saw this before the manufacturers did. They built for speed and conversion. Virtual prescriber access. Lifestyle bundling. Marketing that speaks to how people actually think about weight. Not obesity treatment. Weight loss, energy, confidence.

That positioning works because it matches consumer intent. And it sidesteps the regulatory constraints that pharmaceutical companies face in direct marketing.

The manufacturers are now adopting the same playbook. Starter packs priced for impulse purchase. Transparent pricing tiers. Direct mail fulfillment. These are consumer mechanics applied to prescription drugs.

The clinical establishment has concerns. Valid ones. These medications carry real risks. GI distress, thyroid concerns, rare cases of pancreatitis. Long-term effects aren't fully mapped. Medical supervision exists for reasons.

But supervision doesn't scale at consumer velocity. The system has to choose between controlled access and mass access. The infrastructure required for one undermines the other.

This creates opportunity for whoever can manage both. Platforms that can onboard thousands of patients per week while maintaining baseline safety protocols will dominate. Practices that rely on high-touch clinical models will struggle to compete on price or speed.

The compounding market proved the demand exists outside traditional channels. Cash-pay volumes surged when branded drugs were supply-constrained or insurance-gated. Patients paid $300 to $500 per month rather than wait. That behavior doesn't reverse when pills become available. It accelerates.

The market size projections reflect this. Estimates put obesity drugs at $130 billion by 2030. Some models go higher. Those numbers assume consumer-scale distribution, not clinic-scale distribution.

Which means the infrastructure that supports this market looks less like specialty pharmacy and more like supplement fulfillment. Recurring subscription models. Retention mechanics. Lifecycle marketing. Upsell and cross-sell. These are consumer operations, not medical operations.

The companies that understand this are already building for it. The ones that don't will spend the next two years wondering why volume went elsewhere.

Pills don't just make GLP-1s easier to take. They make them easier to sell, ship, refill, and retain. That changes who can compete and how they compete.

The market isn't going consumer because it's better for patients. It's going consumer because that's what the economics support at this scale.

Over the past decade, I’ve been inside how modern health actually gets delivered, not in theory, but in practice. I’ve seen what happens when access scales faster than infrastructure, when incentives drift, and when good intentions collide with operational reality.

My role has put me close to the decisions that don’t make headlines, the tradeoffs around speed, compliance, cost, quality, and sustainability that ultimately determine whether a model works or quietly breaks.

This newsletter isn’t about products or protocols. It’s about understanding how the system really functions, where friction hides, and why some approaches compound over time while others don’t.

If you’re building, running, or participating in modern health in any real way, this layer matters more than most people realize.

— Chris

Until next time,